Albireo to Report Third Quarter 2021 Financial Results on November 4
28 Oktober 2021 - 2:30PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today announced that
management will host a conference call and live audio webcast
at 10:00 a.m. ET on November 4, 2021, to provide a
business update and review the company’s financial results for the
third quarter ended September 30, 2021.
To access the live conference call by phone, please dial
877-407-0792 (domestic) or 201-689-8263 (international), and
provide the access code 13723976. A live audio webcast will be
accessible from the Media & Investors page of Albireo’s
website, https://ir.albireopharma.com/. To ensure a timely
connection to the webcast, it is recommended that users register at
least 15 minutes prior to the start time. An archived version of
the webcast will be available for replay in the Events &
Presentations section of the Media & Investors page of
Albireo’s website for 3 months following the event.
About AlbireoAlbireo Pharma is a rare disease
company focused on the development of novel bile acid modulators to
treat rare pediatric and adult liver diseases. Albireo’s lead
product, BylvayTM (odevixibat), was approved by the U.S. FDA as the
first drug for the treatment of pruritus in all types of
progressive familial intrahepatic cholestasis (PFIC), and it is
also being developed to treat other rare pediatric cholestatic
liver diseases with Phase 3 trials in Alagille syndrome and biliary
atresia, as well as an Open-label Extension (OLE) study for PFIC.
In Europe, Bylvay has been approved for the treatment of PFIC and
has been submitted for pricing and reimbursement approval. The
Company has also initiated a Phase 1 clinical trial for A3907 to
advance development in adult cholestatic liver disease, with
IND-enabling studies moving ahead with A2342 for viral and
cholestatic liver disease. Albireo was spun out from AstraZeneca in
2008 and is headquartered in Boston, Massachusetts, with its key
operating subsidiary in Gothenburg, Sweden. The Boston Business
Journal named Albireo one of the 2019 and 2020 Best Places to Work
in Massachusetts. For more information on Albireo, please visit
www.albireopharma.com.
Media Contact: Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLauren Sneider,
857-300-1737, lauren.sneider@albireopharma.com
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024